Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial Ruby Khatun Khatun1 Dec 2017 9:30 AM ISTFRANKFURT: Germany's Merck KGaA has suffered a setback in the development of key cancer immunotherapy Bavencio, it has failed in a trial to prolong...
Roche cancer immunotherapy Tecentriq wins EU approval Ruby Khatun Khatun25 Sept 2017 10:17 AM ISTZURICH: Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said.The...
Bristols drug cocktail cuts kidney cancer death risk 37 percent Ruby Khatun Khatun14 Sept 2017 9:25 AM ISTMADRID: A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients,...
Merck to acquire Rigontec, RIG-I therapeutics pioneer, advancing leadership in Immuno-Oncology Ruby Khatun Khatun9 Sept 2017 9:57 AM ISTKENILWORTH, N.J. & MUNICH: Merck, known as MSD outside the United States and Canada, and Rigontec announced that Merck will acquire...